Summary

Eligibility
for people ages 18-69 (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Nicky Mehtani, MD MPH (ucsf)
Headshot of Nicky Mehtani
Nicky Mehtani

Description

Summary

The goal of this clinical trial is to learn whether it is possible to use intramuscular (IM) ketamine in combination with psychotherapy to treat moderate-to-severe methamphetamine use disorder (MeUD) in publicly insured patients with or at-risk for HIV disease. The main questions it aims to answer are:

  • Do publicly insured patients find ketamine-assisted psychotherapy feasible and acceptable as a potential treatment for MeUD?
  • Is IM ketamine safe and tolerable among patients with MeUD?

Participants will:

  • Receive 3 monitored doses of IM ketamine
  • Have 3 preparation and 4 integration psychotherapy visits
  • Report their daily amounts of methamphetamine used prior to, during, and up to 3 months following the intervention

Official Title

Pilot Clinical Trial of Ketamine-assisted Psychotherapy for Methamphetamine Use Disorder and HIV Risk Reduction

Details

Keywords

Methamphetamine Use Disorder, HIV, Methamphetamine withdrawal, Ketamine-assisted therapy, Psychedelic, Sexual Behavior, Methamphetamine, Ketamine-assisted psychotherapy, Chemsex, Ketamine, Psychotherapy

Eligibility

Location

  • San Francisco Department of Public Health accepting new patients
    San Francicso California 94102 United States

Lead Scientist at University of California Health

  • Nicky Mehtani, MD MPH (ucsf)
    Nicky Mehtani, MD, MPH is an assistant professor in the UCSF Division of General Internal Medicine at San Francisco General Hospital.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Nicky Mehtani, MD, MPH
ID
NCT06538285
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 12 study participants
Last Updated